News

AstraZeneca: Great Portfolio, But Not A Great Price

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
Fierce Pharma9h

Enhertu, Keytruda promos put AZ, Merck at the front of the oncology HCP marketing pack: report

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...
pharmaphorum1d

Padcev/Keytruda extends survival in early bladder cancer

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer looks to expand ADC use after positive bladder cancer data

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
Zacks.com on MSN1d

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Biliary Tract Cancer Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape

In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a ...